Diagnosis and Treatment > Investigation > C-peptide (blood)

You are looking at 51 - 51 of 51 items

S Solomou Department of Endocrinology, Barts and the London School of Medicine, QMUL, W SmithfieldEC1A 7BE, London, UK

Search for other papers by S Solomou in
Google Scholar
PubMed
Close
,
R Khan Department of Endocrinology, Barts and the London School of Medicine, QMUL, W SmithfieldEC1A 7BE, London, UK

Search for other papers by R Khan in
Google Scholar
PubMed
Close
,
D Propper Department of Oncology, Barts and the London School of Medicine, QMUL, W SmithfieldEC1A 7BE, London, UK

Search for other papers by D Propper in
Google Scholar
PubMed
Close
,
D Berney Department of Histopathology, Barts and the London School of Medicine, QMUL, W SmithfieldEC1A 7BE, London, UK

Search for other papers by D Berney in
Google Scholar
PubMed
Close
, and
M Druce Department of Endocrinology, Barts and the London School of Medicine, QMUL, W SmithfieldEC1A 7BE, London, UK

Search for other papers by M Druce in
Google Scholar
PubMed
Close

Summary

A 33-year-old male was diagnosed with a metastatic neuroendocrine carcinoma of uncertain primary. He defaulted from follow-up without therapy and some months later developed episodic severe hypoglycaemia, which was found to be associated with inappropriately elevated insulin and C-peptide levels. It was considered likely that the neuroendocrine tumour was the source of the insulin secretion. Diazoxide and somatostatin analogue were used to control hypoglycaemia. Much later in the course of the disease, he developed metabolic derangement, increased skin pigmentation and psychological disturbance, without frankly Cushingoid physical findings. Investigations revealed highly elevated cortisol levels (the levels having previously been normal) with markedly raised ACTH levels, consistent with the co-secretion of ACTH and insulin by the tumour. Treatment with metyrapone improved his psychological state and electrolyte imbalance. Unfortunately, despite several cycles of first-, second- and third-line chemotherapy from the start of the first hormonal presentation onwards, imaging revealed widespread progressive metastatic disease and the patient eventually passed away. This case highlights the importance of keeping in mind the biochemical heterogeneity of endocrine tumours during their treatment.

Learning points

  • The clinical presentation of insulin-secreting tumours includes symptoms of neuroglycopaenia and sympathetic overstimulation.

  • Tumour-associated hypoglycaemia can be due to pancreatic insulinomas, and although ectopic hormone production occurs in a number of tumours, ectopic secretion of insulin is rare.

  • A possible switch in the type of hormone produced can occur during the growth and progression of neuroendocrine tumours and, when treating neuroendocrine tumours, it is important to keep in mind their biochemical heterogeneity.

Open access